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Abstract 
Background: Approximately two‑thirds of individuals presenting to emergency departments in Western Sydney 
have glucose dysregulation, accelerating their risk of cardiovascular disease (CVD). We evaluated the prevalence and 
management of type 2 diabetes (T2D) in cardiology inpatients in Western Sydney. A novel model of care between 
diabetes and cardiology specialist hospital teams (joint specialist case conferencing, JSCC) is described herein and 
aimed at aligning clinical services and upskilling both teams in the management of the cardiology inpatient with 
comorbid T2D.
Methods: Cardiology inpatients at Blacktown‑Mount Druitt Hospital were audited during a 1‑month period.
Results: 233 patients were included, mean age 64 ± 16 years, 60% were male, 27% overweight and 35% obese. 
Known T2D comprised 36% (n = 84), whereas 6% (n = 15) had a new diagnosis of T2D, of which none of the latter 
were referred for inpatient/outpatient diabetes review. Approximately, 27% (n = 23) and 7% (n = 6) of known diabetes 
patients suffered hyper‑ and hypoglycaemia, respectively, and 51% (n = 43) had sub‑optimally controlled T2D (i.e. 
HbA1c > 7.0%); over half (51%, n = 51) had coronary artery disease. Only two patients were treated with an SGLT2 
inhibitor and no patients were on glucagon like peptide‑1 receptor analogues. The majority were managed with met‑
formin (62%) and therapies with high hypoglycaemic potential (e.g., sulfonylureas (29%)) and in those patients treated 
with insulin, premixed insulin was used in the majority of cases (47%).
Conclusions: Undiagnosed T2D is prevalent and neglected in cardiology inpatients. Few patients with comorbid T2D 
and CVD were managed with therapies of proven cardiac and mortality benefit. Novel models of care may be ben‑
eficial in this high‑risk group of patients and discussed herein is the establishment of the diabetes‑cardiology JSCC 
service delivery model which has been established at our institution.
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Background
Given that people with type 2 diabetes mellitus (T2D) are 
more than 2–3 times more likely to die of cardiovascular 
disease (CVD) than people without T2D [1, 2], treatment 
paradigms have favourably shifted from a ‘glucose lower-
ing’ to a ‘cardioprotective’ model of care [3–5]. Recent 
cardiovascular safety and non-inferiority trials of newer 
diabetes therapies show cardiovascular neutrality with 
dipeptidyl peptidase-4 inhibitors (DPP4i [e.g., sitaglip-
tin]) [6] however, there was demonstrable reduction in 
CV mortality and hospitalisation for heart failure (HF) 
with sodium-glucose co-transporter 2 inhibitors (SGLT2i 
[e.g., empagliflozin, canagliflozin, dapagliflozin]) [7–9], 
and CV events with glucagon-like peptide 1 receptor 
agonists (GLP1-RA [e.g., liraglutide, semaglutide]) [10, 
11]; this is in addition to added benefits of modest weight 
loss and improvement in blood pressure also seen with 
these agents.
Considering the robust clinical evidence, the uptake 
of ‘cardioprotective therapies’ may not be as sweeping as 
once thought [12], especially in primary care. These rea-
sons include the lack of clinical inertia, the physician’s 
unfamiliarity with the newer therapies and of monitoring 
mechanisms, cost, side-effect profile [13], and perceived 
invasiveness of the injectable GLP1-RA. Prescribing 
trends in the UK still favoured metformin as the first-
line treatment for T2D among primary care physicians 
(83.6%) however, sulphonylureas remained the second 
most common drug (41.4%), [14] despite the 10–17% 
increase in CV mortality, events, and hypoglycaemia 
[3]; in contrast, GLP-1 RA were rarely prescribed first-
line or after metformin and DPP4i were prescribed at a 
mediocre 15.4%. Insulin prescriptions remained stable at 
20–24% [14]. There is unanimous agreement regarding 
reducing the risk of hypoglycaemia in modern diabetes 
management, yet the same therapies (i.e., sulphonylureas, 
insulins) were being used widely in the community.
Western Sydney is recognised as having one of the 
most metabolically abnormal populations in Australia, 
with nearly two-thirds of all people being tested in ter-
tiary hospital emergency departments having some form 
of glycaemic abnormality (38.4% with T2D, 27.4% with 
prediabetes) using glycosylated haemoglobin (HbA1c) 
measurements taken as part of a screening project [15]. 
Given the emphasis on CV outcomes with newer phar-
macotherapies, this study focussed on admitted patients 
to the cardiology service. We hypothesised that the 
considerable metabolic burden of disease known in our 
region, would lead us to identify a large gap between 
evidence-based clinical management and real-world 
findings. Our aims were to evaluate the prevalence of 
metabolic disease in this cohort, audit the clinical and 
financial outcomes, and evaluate pharmacologic burden 
in those with T2D. Importantly, we endeavoured to cap-
ture the potential opportunities that exist in improving 
diabetes management in this high-risk group, with a 
view towards enhancing the collaboration between dia-
betes and cardiology services through joint specialist 
case conferencing (JSCC), a novel model of care that has 




A 1-month retrospective audit was undertaken of all 
patients admitted under the Cardiology Service through 
the Emergency Department in the month of September 
2016 in Blacktown Mt Druitt Hospital, Western Sydney 
Local Health District (New South Wales, Australia). The 
hospital uses electronic medical records for documen-
tation such that all progress notes, medications, patient 
information and results of investigations (pathology and 
radiology) are collected and accessible via a secure user 
defined, login process.
Data collection
Data collected was de-identified and included basic 
demographic information, weight (overweight, body 
mass index [BMI] 25–29.9  kg/m2; obese, BMI ≥ 30  kg/
m2) and as having either incident or known predia-
betes (HbA1c 39 to 46  mmol/mol, 5.7–6.4%) or T2D 
(HbA1c ≥ 48  mmol/mol or 6.5%) based on established 
definitions. Duration of diagnosis, diabetes treatment 
and the presence of micro- (retinopathy, neuropathy, 
nephropathy) and macrovascular (CV disease, peripheral 
vascular, cerebrovascular disease) complications were 
also obtained.
Primary reasons for admission, presence of coronary 
artery disease (CAD), HF, left ventricular ejection frac-
tion (LVEF), valvular disease, the presence of other 
comorbid cardiopulmonary disease, risk factors, medi-
cations and laboratory data were obtained from the his-
tory or investigations (e.g., angiogram, echocardiogram). 
Cost of the inpatient stay was determined using national 
weighted activity unit (NWAU), a nationally standardised 
costing of health service activity, as well as the presence 
of hyper- or hypoglycaemia. Engagement with the diabe-
tes service (referrals to diabetes educator and/or endocri-
nology registrar) were also documented to assess service 
utilization. This study was approved by the local human 
research committee.
Exclusions
We excluded individuals with Type 1 diabetes, admis-
sions for elective procedures (e.g., elective angiograms 
or percutaneous coronary interventions/angioplasty, DC 
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cardioversion for atrial fibrillation/flutter, to perform 
transthoracic echocardiograms, awaiting preparation for 
coronary artery bypass graft procedure) readmissions 
within the audit month, incorrect admissions under car-
diology and individuals not admitted through the emer-
gency department. Admissions for elective procedures 
were defined using hospital coding as any admission that 
had a code of “elective”, no specific procedures were iden-
tified in the audit.
Statistical analysis
All statistical analysis was conducted using SPSS soft-
ware. Continuous variables were compared using a stand-
ard t-test, and categorical variables using Chi squared 
methodology. Bonferroni’s method was used to control 
for multiple comparisons, with p-values presented after 
correction.
Results
Identified patients included 311 of which 235 were 
included in the analysis (51 excluded due to elective pro-
cedures, 25 when the exclusion criteria was applied); 136 
were non-T2D and 99 had T2D (Table  1), indicating a 
prevalence of 42% for T2D. Study participants with T2D 
were more likely to be older, more overweight or obese 
and have a longer length of stay by nearly 2 days (43 h); 
gender distribution among T2D cohort was equal. The 
T2D cohort were almost four times more likely to pre-
sent with IHD (mostly ST segment elevation myocar-
dial infarction, STEMI) and nearly twice the rates of 
heart failure then the non-diabetic group (all p < 0.0001; 
Table  1). The NWAU also appeared to be higher in the 
T2D versus non-T2D cohort, although this was not sta-
tistically significant (p = 0.07).
Despite half of the non-T2D population having predia-
betes based on screening HbA1c, participants with T2D 
had higher prevalence of CAD (p = 0.024), hypertension 
(p < 0.001), and dyslipidaemia (p = 0.002) but similar 
rates of stroke, previous PCI, HF and previous smoking 
(all p > 0.05; Table  2). There was higher pharmacologic 
burden in T2D patients (p = 0.002), with higher use of 
aspirin, angiotensin II receptor blockers, and loop diu-
retics, although likely due to the small subgroup sample 
size none of these values were statistically significant 
(p > 0.05). Of note, there was low uptake of ACEi or 
ARB in patients with T2D comorbid HF (39%, data not 
shown).
Incident T2D cases were found in 14 patients (Table 3), 
of whom none were referred to the diabetes service or 
recommended for either general physician or special-
ist review on discharge; only a fraction had the diagno-
sis mentioned in their discharge letter (21%) or coded 
appropriately as a new diagnosis in the medical record 
(36%). Morbidity in the overall T2D cohort was high 
with micro- and macrovascular complications present in 
40% and 63%, respectively. Referral to the diabetes ser-
vice was low (9% of prevalent and 0% in incident cases). 
Most patients were managed with metformin and/or 
sulphonylureas being the second most common therapy 
prescribed, whereas SGLT2i and GLP1-RA were rarely 
prescribed and insulin use was dominated by premixed 
preparation (47%) with an out-of-target mean HbA1c 
(68 mmol/mol or 8.4%).
Table 1 Comparison of  demographic, clinical 
and admission characteristics between study participants 
in those with and without type 2 diabetes mellitus
Values are shown as N (%) and mean ± SD; T2D, type 2 diabetes mellitus. 
*denotes statistical significance at P value < 0.05; **indicates some data missing 
or not recorded; ***denotes significant differences in distribution using Chi 
square test (P value < 0.05). Values in parentheses indicate percentage of the 
cohort; NS not statistically significant
Parameter Non-T2D T2D P-value
N 136 99
Male (N, %) 85 (63%) 54 (54%) NS
Mean age (years) 62 ± 17 67 ± 13 < 0.01*
Country of birth
 Australia/NA 88 84 NS
 Europe 17 19 NS
 Asia 10 15 NS
 Middle East 6 5 NS
 India 6 4 NS
 Pacific Islands 5 6 NS
 Aboriginal/Torres Strait Islander 3 1 NS
 New Zealand 3 1 NS
 Africa 1 1 NS
Overweight (BMI 25–29.9 kg/
m2) (N)**
41** 21** 0.001*
Obese (BMI ≥ 30 kg/m2) (N)** 37** 45**  0.01*
Pre‑diabetes (N; %) 72 (53) – –
Body mass index (kg/m2) 28 ± 5 32 ± 8 < 0.001*
Glycosylated haemoglobin (HbA1c)
 mmol/mol 39 ± 3 55 ± 9  < 0.001* 
 % 5.7 ± 0.4 7.3 ± 1.3
Admission details
Primary reason for admission
 Chest pain 35 (26) 28 (29)  < 0.0001***
 Ischaemic heart disease 7 (5) 21 (21)
 Heart failure 13 (10) 18 (18)
 Arrhythmias 35 (26) 9 (9)
 Other heart disease 24 (18) 11 (11)
 Other (deemed non‑cardiac) 21 (15) 12 (12)
Length of stay (hours) 101 ± 130 144 ± 140  0.01*
National weighted activity unit 
(NWAU)
1.35 ± 1.52 1.72 ± 1.46  0.07
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Table 2 Comparison of  cardiac history, risk factors and  pharmacotherapy between  study participants in  those 
with and without type 2 diabetes mellitus
Values are shown as N (%) and mean ± SD; LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol. *denotes statistical significance at P 
value < 0.05; **indicates some data missing or not recorded; ***denotes significant differences in distribution using Chi square test (P value < 0.05); #T2D cohort—PCI 
revealed disease in 17 involving left anterior descending artery, 15 left circumflex, 14 right coronary artery, and 4 left main. Values in parentheses indicate percentage 
of the cohort; NS not statistically significant
Parameter Non-T2D T2D P-value
N 136 99
Coronary artery disease (N; %) 50 (37) 51 (51)  0.024*
Stroke (N; %) 8 (6) 12 (12) NS
Previous coronary revascularisation 33 (24) 32 (32)
Percutaneous coronary  intervention# 24 (18) 23 (23)
Coronary artery graft surgery 12 (9) 14 (14)
Heart failure 42 (31) 33 (33)
 Left ventricle ejection fraction ≤ 40% 51 ± 18 53.6 ± 15.6
Previous arrhythmia 49 (36) 26 (26)
Valvular disease 51 (38) 36 (36)
Cardiopulmonary disease and other risk factors
Current smoker (N; %) 23 (17) 14 (14) NS
Ex‑smoker (N; %) 36 (26) 32 (32)
Pulmonary hypertension 18 (13) 18 (18)
Hypertension 80 (59) 80 (80)  < 0.001*
Dyslipidaemia 56 (41) 61 (61)  0.002*
NS Total cholesterol (mmol/L) 4.3 ± 1.3 4.0 ± 1.4
 LDL‑c (mmol/L) 2.4 ± 1.1 2.2 ± 1.9
 HDL‑c (mmol/L) 1.1 ± 0.2 0.9 ± 1.1
 Triglycerides (mmol/L) 1.7 ± 0.8 3.3 ± 2.1
Chronic obstructive pulmonary disease 9 (7) 10 (10) NS
Asthma 18 (13) 14 (14) NS
Cardiac medications
 Aspirin 38 (28) 50 (50)   0.002*
 Dual anti‑platelet agents 10 (7) 16 (16) NS
 Clopidogrel 13 (10) 18 (18)
 Prasugrel 1 (0.7) 2 (2)
 Ticagrelor 2 (1) 2 (2)
 Warfarin 5 (4) 5 (5)
 Non‑vitamin K antagonist oral anticoagulants 18 (13) 9 (9)
 Nitrates 9 (7) 10 (10)
 Ivabradine 2 (1) 3 (3)
 Digoxin 16 (12) 5 (5)
 Beta‑blockers 44 (32) 44 (44)
 Alpha‑blockers 9 (7) 9 (9)
 Calcium channel blocker 22 (16) 22 (22)
 Angiotensin converting enzyme inhibitors 31 (23) 19 (19)
 Angiotensin II receptor blockers 31 (23) 44 (44)  0.002*
 Thiazide diuretic 9 (7) 12 (12) NS
 Loop diuretic 21 (15) 32 (32)  0.007*
 Aldosterone receptor blocker 10 (7) 11 (11) NS
 Centrally‑acting antihypertensive 1 (< 1) 1(1)  < 0.001*
 Statins 61 (45) 73 (74) NS
 Ezetimibe 8 (6) 12 (12)
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Very few patients had an accurate documentation 
of duration of diagnosis of T2D and therefore this 
was not included. In total, 6 patients had documented 
hypoglycaemia (BGL < 4.0  mmol/L) of whom all were 
on either insulin or sulphonylurea, and 35 experienced 
hyperglycaemia (BGL ≥ 14  mmol/L) during their hos-
pital admission.
Discussion
Nearly 70% of people with T2D will die of CVD [16] 
therefore, focussing efforts to intensify case detection 
and enhance diabetes management to positively affect 
the long-term quality of life and survival in T2D patients 
is a major health priority.
Our audit revealed that people with T2D made up 
nearly 2 in 5 cardiology inpatients (14% were new diagno-
ses) and that T2D participants were unsurprisingly more 
obese or overweight, have comorbid CAD, stroke and 
as well as higher pharmacologic use than the non-T2D 
cohort. They were also more likely to present with heart 
failure (10 vs 18%, p < 0.0001, Table  1). In community-
dwelling older adults (65–74 years—similar to our study 
mean age), national data reveals that among those with 
CVD, T2D was comorbid in 19.4%; conversely, those with 
T2D, CAD was present in 10.6%, HF in 8.2% and cerebro-
vascular disease in 2.4% [17]. In contrast, our study sam-
ple had nearly 5×, 4× and 5× the rates of CAD (51%), HF 
(33%) and cerebrovascular disease (stroke or TIA, 12%), 
suggesting the presence of increased disease burden due 
to hospital bias of admitted patients. We found that none 
of the incident and only 9% of prevalent T2D cases were 
referred for inpatient review (11% for outpatient review), 
illustrating the need to increase communication between 
the cardiology and diabetes services to better deliver care 
in this high-risk group.
Our study revealed that 47% of insulin-requiring patients 
were on premixed insulin, and that after metformin, sulph-
onylureas were the most commonly prescribed oral agent 
(29%). Both therapies are more likely to be associated with 
hypoglycaemia and weight gain, and adversely affect indi-
viduals with CVD, particularly given the association of 
hypoglycaemia with arrhythmia and sudden death [3, 18, 
19], as well as the blunted hypoglycaemic awareness in the 
context of beta-blocker use in these patients.
In addition to positively improving glycaemic con-
trol, many of the ‘newer’ diabetes therapies (i.e., SGLT2i, 
GLP1-RA, DPP4i) have extra-glycaemic benefits, such as 
reduction in LDL-c, improvements in HDL-c, stabilisa-
tion of endothelial cells, reduction in inflammation, regu-
lating adipokine release with the added benefits of weight 
loss [20]. The low uptake of these drugs suggests that 
these therapies are not being appropriately considered 
locally in CVD patients with T2D. In fact, the Food and 
Drug Administration added a cardiovascular mortality 
indication in 2016 for empagliflozin, and both semaglu-
tide and liraglutide have shown CV benefits as noted pre-
viously [10, 11]. Consequently, national and international 
guidelines should give consideration to escalating these 
new therapies as second line treatment in preference over 
Table 3 Characteristics and  management of  study 
participants with type 2 diabetes mellitus
Parameter N = 99
Incident T2D 14 (14%)
 Referred for inpatient diabetes review 0/14
 New diagnosis mentioned in discharge letter 3/14 (21%)
 New diagnosis coded for in medical record 5/14 (36%)
 Recommended for endocrinology review after discharge 0/14
Known T2D 85 (85%)
 Referred for inpatient diabetes review 9/85 (11%)
 Diagnosis mentioned in discharge letter 82/85 (96%)
 Diagnosis coded for in medical record 82/85 (96%)
 Recommended for endocrinology review after discharge 11/85 (13%)
Management of known T2D 85 (85%)
 Hyperglycaemia 23/85 (27%)
 Hypoglycaemia 6/85 (7%)
 HbA1c > 7% (> 53 mmol/mol) 43/85 (56%)
Microvascular complications 40 (40%)
 Peripheral neuropathy 7 (7%)
 Retinopathy 5 (5%)
 Nephropathy (2 on dialysis) 46 (46%)
Macrovascular complications 63 (63%)
 Coronary artery disease 51 (51%)
 Ischaemic heart disease 53 (53%)
 Peripheral vascular disease 6 (6%)
 Carotid stenosis 4 (4%)
 Stroke/transient ischaemic attack 12 (12%)
Diabetes treatment
 Metformin 61 (62%)
 Sulphonylurea 29 (29%)
 Dipeptidyl peptidase‑4 inhibitor 13 (13%)
 Sodium glucose co‑transporter 2 inhibitor 2 (2%)
 Glucagon‑like peptide‑1 receptor analogue 0
 Acarbose 0
 Thiazolidinediones 0
 None 26 (26%)
 Insulin 17 (17%)
  Mean total daily dose (U) 77.7 ± 53
  Basal (mean HbA1c 78 mmol/mol, 9.3%) 4/17 (24%)
  Premixed (mean HbA1c 68 mmol/mol, 8.4%) 8/17 (47%)
  Basal‑bolus (mean HbA1c 56 mmol/mol, 7.3%) 5/17 (29%)
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the use of sulphonylureas (and provide clear contraindi-
cations for the use of thiazolidinediones) for people with 
T2D and CVD.
We commenced this audit to establish a more compre-
hensive approach to the problem of CV morbidity and 
mortality in T2D patients, specifically with the use of a 
novel integrated model of care using JSCC. Joint Special-
ist Case Conferencing comprises of an integrated discus-
sion about a patients’ diabetes management between the 
diabetes specialist, resident, diabetes educator, patient 
and primary care physician and is carried out in the pri-
mary care clinic for 30-min consultations per patient. We 
have previously shown that JSCC lead to benefits after 
a single visit to primary care physicians, including an 
absolute reduction of − 0.87% in HbA1c and reductions 
in blood pressure, lipid profile and weight, and that the 
results were durable to 3-years [21].
Given that many cardiology inpatient services are pri-
marily focused on the immediate management of acute 
and subacute emergencies, chronic conditions such 
as T2D may be overlooked. As such, we have similarly 
instituted JSCC with our cardiology hospital special-
ist team on a monthly basis in a modified format (i.e., 
patient not present but discussed in a round table set-
ting with clinicians and diabetes educators and cardiol-
ogy nurses present, see Fig. 1), with a focus on building 
capacity within the cardiology specialist team to better 
manage diabetes, with added benefits of increasing com-
munication and collaboration between the departments. 
A protocol for the management of diabetes with a focus 
on cardiovascular outcomes is also being developed. A 
second follow-up audit is planned to assess the impact 
of this intervention in an age- and gender-matched 
cohort. Limitations of the study include its retrospective 
nature, which is inherent in audit-type studies, as well as 
lack of mortality data; follow-up studies are in progress.
Conclusions
Altogether, this audit reveals the high prevalence of 
T2D in one of the most metabolically challenging, 
populations in Australia where there is a high burden 
of concurrent CVD. Greater collaboration should be 
sought in all tertiary hospitals where both cardiology 
and diabetes teams co-exist and a format similar to the 
JSCC model described here be considered to strengthen 
the diabetes-cardiology clinical service interface. Car-
dioprotective diabetes therapies have a unique niche 
in the CV patient with concomitant T2D and should 
guide appropriate management to reduce mortality and 
morbidity in this high-risk group.
Fig. 1 Schema of joint specialist case conferencing (JSCC) between diabetes and cardiology specialist teams. A novel model of care between both 
inpatient hospital teams to align, upskill and enhance hospital management of the cardiology inpatient with diabetes. JMO junior medical officer, 
CDE certified diabetes educator
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